Pharmacokinetic study of salvianolic acid D after oral and intravenous administration in rats.
10.1016/j.apsb.2015.03.015
- Author:
Junke SONG
1
;
Wen ZHANG
1
;
Jialin SUN
2
;
Xiaona XU
1
;
Xue ZHANG
1
;
Li ZHANG
1
;
Zhangying FENG
3
;
Guan-Hua DU
1
Author Information
1. State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Beijing Key Laboratory of Drug Target Identification and Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
2. Pharmacy Department of the Affiliated Hospital of Medical College of Qingdao University, Qingdao 266003, China.
3. The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
- Publication Type:Journal Article
- Keywords:
AUC, the area under curve;
Analysis method;
Bioavailability;
CI, confidence interval;
CL, clearance;
Cmax, peak plasma concentration;
Danshen;
Dose proportionality;
ECE-1, endothelin converting enzyme 1;
ESI, electrospray ionization;
IS, internal standard;
LC-MS;
LLOQ, lower limit of quantification;
Pharmacokinetics;
QC, quality control;
R.E., relative error;
R.S.D., relative standard deviation;
SIM, single ion monitoring;
SalB, salvianolic acid B;
SalD, salvianolic acid D;
Salvia miltiorrhiza;
Salvianolic acid D;
TCM, traditional Chinese medicine;
ULOQ, upper limit of quantification
- From:
Acta Pharmaceutica Sinica B
2015;5(3):246-253
- CountryChina
- Language:English
-
Abstract:
A sensitive, specific and rapid LC-MS method was developed and validated for the determination of salvianolic acid D (SalD) in rat plasma. This method used a single quadrupole mass spectrometer with an electrospray ionization (ESI) source. A single ion monitoring scanning (SIM) mode was employed. It showed good linearity over the concentration range from 3.3 to 666.7 ng/mL for the determination of SalD. The R.S.D.% of intra-day and inter-day precision values were no more than 7.69%, and the accuracy was within 91%-104% at all quality control levels. This LC-MS method was applied to the pharmacokinetic study of SalD in rats. A two-compartmental model analysis was employed. The plasma concentrations at 2 min (C 2min) were 5756.06±719.61, 11,073.01±1783.46 and 21,077.58±5581.97 μg/L for 0.25, 0.5 and 1 mg/kg intravenous injection, respectively. The peak plasma concentration (C max) was 333.08±61.21 μg/L for 4 mg/kg oral administration. The area under curve (AUC0-t ) was 14,384.379±8443.184, 22,813.369±11,860.823, 46,406.122±27,592.645 and 8201.740±4711.961 μg/L·h for intravenous injection (0.25, 0.5 and 1 mg/kg) and oral administration (4 mg/kg), respectively. The bioavailability of SalD was calculated to be 4.159%±0.517%.
